SomaLogic (LAB)

Executive Summary

SomaLogic is a proteomics company that has developed the SomaScan platform, a high-throughput, multiplexed protein measurement technology capable of quantifying thousands of proteins from small sample volumes. The platform enables deep insights into the human proteome and is used for biomarker discovery, translational research, and diagnostic development across a wide range of diseases. With a focus on transforming research and healthcare, SomaLogic has established a strong intellectual property portfolio and commercial partnerships. The company has a valuation of approximately $387 million and is publicly traded under the ticker LAB. Despite being categorized as pre-clinical, SomaLogic has significant revenue potential from its services and licensing agreements. The company's ability to provide comprehensive proteomic data positions it well in the growing precision medicine market. Key near-term catalysts include potential FDA clearances for diagnostic tests, expansion of its test menu, and new collaborations with pharmaceutical and academic institutions. SomaLogic's financial stability and innovative platform make it a compelling investment opportunity in the diagnostics sector.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance of SomaScan-based diagnostic test for early cancer detection60% success
• Q2 2026Announcement of major partnership with a top-20 pharmaceutical company for drug development75% success
• Q4 2026Launch of new SomaScan panel covering neurological diseases80% success